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reamble
he American College of Cardiology Foundation (ACCF)/
merican Heart Association (AHA)/American College of
hysicians (ACP) Task Force on Clinical Competence was
ormed in 1998 to develop recommendations for attaining
nd maintaining the cognitive and technical skills necessary
or the competent performance of a specific cardiovascular
ervice, procedure, or technology. These documents are
vidence-based, and where evidence is not available, expert
pinion is utilized to formulate recommendations. Indica-
ions and contraindications for specific services or proce-
ures are not included in the scope of these documents.
ecommendations are intended to guide curriculum devel-
pment and assist those who judge the competence of
ardiovascular healthcare providers entering practice for the
rst time and/or those in practice who undergo periodic
eview of their expertise or who apply for privileges at a new
nstitution. The assessment of competence is complex and
ultidimensional; therefore, isolated recommendations
ontained herein may not necessarily be sufficient or appro-
riate for judging overall competence. The current docu-
ent addresses a curriculum for developing competence in
he prevention of cardiovascular disease (CVD) and is
uthored by representatives of the ACCF, AHA, ACP, the
merican Academy of Neurology; American Association of
ardiovascular and Pulmonary Rehabilitation; American
ollege of Preventive Medicine; American College of
ports Medicine; American Diabetes Association (ADA);
merican Society of Hypertension; Association of Black
ardiologists; Centers for Disease Control and Prevention;
ational Heart, Lung, and Blood Institute; National Lipid
ssociation; and the Preventive Cardiovascular Nurses As-
ociation. The recommendations contained herein recog-
ize the broader context of clinical training and the impor-
ance of systems of care in improving patient outcomes.
rainees should be aware of and responsive to the larger
ontext of systems-based health care and utilize all available
esources to provide optimum care. Similarly, the develop-
ent of competence embodies knowledgeable incorporationf technological advances for the evaluation of health and fisease based on ongoing familiarity with the emerging
cientific and social literature.
The ACCF/AHA/ACP Task Force makes every effort to
void actual or potential conflicts of interest that may arise
s a result of an outside relationship or personal interest of
member of the ACCF/AHA/ACP Writing Committee.
pecifically, all members of the writing committee are asked
o provide disclosure statements of all such relationships
hat might be perceived as real or potential conflicts of
nterest relevant to the document topic. These statements
re reviewed by the writing committee and updated as
hanges occur. The relationships with industry for authors
nd peer reviewers are published in Appendixes 1 and 2 of
he document.
Jonathan L. Halperin, MD, FACC
Chair, ACCF/AHA/ACP Task Force
on Competence and Training
. Introduction
he mission of many organizations is providing optimal
are to those with or at risk of developing CVD (primary
nd secondary prevention). Over the past 2 decades, there
ave been dramatic increases in knowledge concerning
pecific risk factors in atherosclerosis, hypertension, throm-
osis, and other forms of vascular dysfunction. Clinical trials
ave proven that strategies aimed at the appropriate detec-
ion and modification of risk factors can slow progression of
therosclerosis, diabetes mellitus, and hypertension and
educe the occurrence of clinical cardiovascular events in
oth primary and secondary prevention settings. More
ecently, it has been shown that atherosclerosis can be
tabilized or even modestly reversed. Finally, a new and
rowing knowledge base of molecular genetics applied to
he study of the cardiovascular system has potential rele-
ance to the clinical practice of preventive cardiovascular
edicine.
Despite the fact that clinical outcomes can be improved
y promotion of favorable life habits and behaviors and by
he proper use of drug treatment, the application of primary
nd secondary preventive interventions in clinical practice is
ot optimal. Prevention of CVD in both the primary and
econdary prevention setting, while dominantly the respon-
ibility of the primary care provider, is increasingly chal-
enged given the ever expanding new knowledge as well as
he ongoing problems related to adherence to recommen-
ations. New knowledge in the area of preclinical disease
etection has presented increasingly challenging scenarios to
rimary care healthcare providers relative to the decisions
egarding the need for further risk stratification and aggres-
ive medical regimens. Furthermore, increasingly complex
atients are surviving with CVD, many of whom can benefit
rom advanced knowledge and expertise with regard to risk
actor management and rehabilitation that is beyond the
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cope of practice.
The prevention of cardiovascular morbidity and mortality
s a shared responsibility among all health professionals
nvolved in the care of people at risk of developing CVD.
his document is directed at those individuals seeking
xpertise at a leadership level in this field, and includes
pportunities for formal training and alternative routes to
ompetence and maintenance of competence in prevention
f CVD (Table 1) (1–5), and educational resources for
cquisition and maintenance of competence in the preven-
ion of CVD (Table 2) (6–43). To address the expanding
und of knowledge in the area and to ensure that an
dequately trained force of preventive cardiovascular leaders
ill be available to primary care providers, as well as to
rovide a pool of providers with expertise in running
ehabilitation and other programs designed to address the
ngoing issue of adherence, the formulation of clinical
ompetency criteria for the cardiovascular preventive special-
st is needed. These competency criteria are expected to address
ssues of expert clinical and scientific leadership, specialty
atient care and consultation, and directorship of primary and
econdary preventive cardiac programs. Of note and similar to
ther subspecialty areas of medicine, cardiovascular preventive
pecialists will have varying areas of expertise and will not
ecessarily achieve all of the outlined areas of competencies.
hese clinical competency criteria in the area of specialty
reatment and prevention of CVD are needed given the current
etting of a rapidly growing field of knowledge ranging from
olecular and cellular mechanisms to clinical outcomes in
rder to translate this into improved patient care.
C. Noel Bairey Merz, MD, FACC, FAHA
Chair, ACCF/AHA/ACP Writing Committee to
Develop a Competence and Training Statement
on Prevention of Cardiovascular Disease
. Cardiovascular and Vascular Biology
.1. Justification
ecent advances in cardiac and vascular biology and related
olecular and cellular mechanisms provide a sound scientific
oundation for the practice of preventive cardiovascular medi-
ine. A basic knowledge of the structure and function of the
rterial wall, its interactions with components of the circulating
lood, and key pathologic processes such as oxidation, inflam-
ation, thrombosis, and remodeling is important to the
pplication of strategies for the detection, evaluation, and
revention of atherosclerotic CVD (44,45). Similarly, a basic
nderstanding of myocardial cellular and molecular processes is
ssential for effective application of therapies that address
yocardial salvage, regeneration, and remodeling.
.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in: e. The process of atherosclerosis that begins in youth,
initially as a fatty streak containing mainly lipid-rich
macrophages in the arterial intima (46), and the role of
various blood lipoproteins in this process and the factors
that promote the initiation and progression of the fatty
streak to arterial plaque (including endothelial activation
and dysfunction, smooth muscle cell migration and prolif-
eration, collagen production, and arterial remodeling).
. Disorders of lipid metabolism and major atherogenic risk
factors, and the pathophysiological significance of the
biological composition of the arterial plaque and its
fibrous cap (47,48).
. A substantial understanding of vulnerable plaque and the
crucial role of inflammation, plaque fissuring, erosion,
and rupture in the genesis of acute coronary syndromes,
should be emphasized. An understanding of the concepts
of plaque pathophysiology remodeling and progression
should also be understood, as well as an appreciation of
the systemic nature of atherosclerosis.
. Systemic (endocrine) and local (autocrine/paracrine)
neurohormonal derangements that lead to an impaired
vasoregulatory and fibrinolytic balance, including the
biological, social, and environmental determinants of
these derangements as well as the pharmacologic and
therapeutic lifestyle changes established for their control.
. Mechanisms of atherosclerosis-specific targeted interven-
tions with the use of combination medications that can be
used to slow progression and reverse the process (49).
. Vascular and hemodynamic benefits of smoking cessa-
tion, increased physical activity, and a diet low in
saturated fats and rich in fruits, vegetables, fiber, and
whole grains, particularly promoted at an early age.
. Clinical Epidemiology and Biostatistics
.1. Justification
linical epidemiology is the study of the magnitude, distri-
ution, and trends in the factors that affect health, disease,
nd their determinants in populations. Within the context
f preventive cardiology, clinical epidemiology provides
rucial information in the enumeration of CVD events,
ates, trends, and outcomes in defined populations and their
ubgroups. It also permits the identification of populations
t different levels of risk for CVD events and the existence
f health disparities (51). The surveillance components of
linical epidemiology provide clues to new and emerging
VD threats and permit assessment of the effectiveness of
nterventions.
Recent emphasis on quality, economic end points, and
odeling in epidemiologic studies provides an opportunity
or epidemiology to inform clinical practice on the cost-
ffectiveness and health impact of alternative preventive
trategies (52–55). In addition, clinical epidemiology serves
n important role in informing practitioners about the use of
vidence from clinical trials and the strength and general-
Table 1. Opportunities for Formal Training and Alternative Routes to Competence and Maintenance of Competence in Prevention of Cardiovascular Disease
Section
A
Ways to Achieve Formal Training
B
Alternate Routes to Achieve Competence
C
Maintenance of Competence
2. Cardiovascular and Vascular Biology ACCF Self-Assessment programs (ACCSAP,
LipidSAP)
CME that focuses on cardiovascular and vascular biology and
atherosclerosis is important to receive each year
3. Clinical Epidemiology and
Biostatistics
ACCSAP
The AHA 10-Day Seminar on the Epidemiology and
Prevention of CVD
5. Genetics and Cardiovascular
Disease in Individuals and Families
Participation in an active genetic CVD referral clinic
under the supervision of expert cardiovascular
specialists in the relevant areas
CME that focuses on the genetic aspects of CVD prevention
in individuals and families is important to receive each
year
6. Behavioral and Psychosocial
Programs (Financial and
Socioeconomic Factors)
Participation in cardiac rehabilitation program that
includes psychosocial assessment, management,
and referral under the supervision of expert
cardiovascular and other specialists in the
relevant areas
CME that focuses on behavioral assessment and
management of patients with CVD
10. Nutrition Management Clinical experience in a preventive cardiology clinic
program during formal fellowship training.
Clinical experience in nutrition subspecialty
programs such as weight loss clinics, lipid
clinics, and diabetes management programs
11. Lipid Management (Management
of Dyslipidemia)
A comprehensive understanding of the NCEP ATP
III and updates is critical to achieve
competence. The ACCF provides a self-
assessment program in lipidology, and the
National Lipid Association has a self-study
program that can provide eligibility for Board
certification by the American Board of Clinical
Lipidology
National Lipid Association sponsored self-assessment
program, self-study modules, masters class, and advanced
masters summits in lipidology
12. Thrombosis Management ACCF/AHA continuing education programs, the
American College of Chest Physician Consensus
Conference Guidelines, the Peripheral Arterial
Diseases Antiplatelet Consensus Group:
Antithrombotic and thrombolytic therapy:
American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines (1)
Web sites of the PAD Coalition and AHA National society meetings with focus on antithrombotic
therapy
13. Hypertension Management American Society of Hypertension Certification as a
clinical specialist in hypertension and medical
education seminars and didactic sessions with
faculty members with expertise in each of the
above areas
14. Smoking Cessation Formal training in behavioral science and smoking
cessation is a critical link to successful office-
based or hospital-based smoking cessation
programs. Mentoring by faculty/colleagues with
expertise in behavioral medicine/science is an
important training modality
Medical education seminars, Webcast CME
programs, Society for Behavioral Medicine
publications and meetings, and CME programs
specifically addressing addiction and smoking
cessation
National Cancer Institute Web site: Prevention and Cessation
of Cigarette Smoking: Control of Tobacco Use (2)
MedlinePlus: Quitting Smoking (3)
AHA Web site: Smoking and Cardiovascular Disease (4)
CDC Web site: Smoking & Tobacco Use
Continued on next page
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Table 1. Continued
Section
A
Ways to Achieve Formal Training
B
Alternate Routes to Achieve Competence
C
Maintenance of Competence
15. Obesity Management (Behavioral
Programs)
A clinical rotation in both an endocrinology and a
bariatric surgery–based obesity clinic to learn
how to apply patient-specific behavioral
methods to achieve weight loss should be
mandatory, with a suggested involvement in the
care of 5 patients entering a weight loss
management program over the course of formal
training. Attendance at an accredited obesity
training program for healthcare professionals.
Continued clinical practice as well as yearly CME courses in
preventive cardiology with a focus on overweight/obesity
management
16. Exercise Physiology, Physical
Activity Management, and Cardiac
Rehabilitation (Secondary
Prevention)
Active instruction in a preventive
cardiology/cardiac rehabilitation center that
includes access to a multidisciplinary staff (e.g.,
cardiologists with specific expertise/training in
secondary prevention, nurse clinicians, exercise
physiologists, registered dieticians, behaviorists,
smoking cessation counselors, and
pharmacists). A listing of cardiopulmonary
rehabilitation programs in the United States and
Canada is available through the American
Association of Cardiovascular and Pulmonary
Rehabilitation. Moreover, the American College
of Sports Medicine offers certification
examinations and registry programs for exercise
physiology, as well as a complete listing of the
knowledge, skills, and abilities that comprise
the foundations of these relevant certifications
(e.g., exercise specialist, registered clinical
exercise physiologist), with specific reference to
requirements (e.g., educational degree,
minimum hours of practical experience) and
recommended competencies (5).
Direct clinical training with exercise physiologists,
smoking cessation counselors, registered
dieticians, and lipid specialists in settings other
than formal cardiac rehabilitation programs
Active involvement with cardiac rehabilitation/secondary
prevention programs and direct involvement in the
supervision and care of cardiac rehabilitation patients
each year. CME that focuses on clinical exercise physiology
applications, exercise prescription in health and disease,
and cardiac rehabilitation/secondary prevention are
important to receive each year. Organizations with related
regional and national conference programming include:
ACCF; AHA; American College of Sports Medicine; and the
American Association of Cardiovascular and Pulmonary
Rehabilitation
17. Prediabetes, Metabolic Syndrome,
Insulin Resistance, and Diabetes
Management
Clinical experience in a preventive cardiovascular
medicine clinic program during formal
fellowship training, as well as rotations in a
specialized diabetes clinic. ADA training
modules with multiple choice questions and
detailed, evidence-based answers.
ADA clinical practice guidelines are updated annually and
published as a supplement to Diabetes Care
18. Chronic Disease Management Clinical rotation in a preventive cardiology center
to learn about and apply a patient-specific,
systems approach to prevention of CVD in
primary and secondary prevention patients
A indicates use of ACCF/AHA training modules with multiple choice questions and detailed, evidence-based answers during training with mentoring by faculty members with expertise in each of the specified areas;B indicates medical education seminars and didactic sessions with faculty members
with expertise in each of the above areas; andC indicates CME activities that focus in each of the specified areas. Use American Board of Internal Medicine recertification modules in the relevant area. ACCF indicates American College of Cardiology Foundation; ADA, American Diabetes Association;
AHA, American Heart Association; CDC, Centers for Disease Control and Prevention; CME, continuing medical education; CVD, cardiovascular disease; and NCEP ATP, National Cholesterol Education Program Adult Treatment Panel III. 1341
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Competence and Training for Prevention of CVD September 29, 2009:1336–63able 2. Educational Resources for Acquisition and Maintenance of Competence in the Prevention of Cardiovascular Disease
Section Educational Opportunities
. Cardiovascular and Vascular Biology (6)
. Clinical Epidemiology and Biostatistics (7–10)
. Cardiovascular Pharmacology (Complex
Multipharmacologic Understanding)
Micromedex is available in many hospitals for dosing and interactions information
Facts and Comparisons page is useful to check for drug–drug interactions
. Genetics and Cardiovascular Disease in Individuals
and Families
(6,11)
National Coalition for Health Professionals Education in Genomics—competencies in genomics
CDC genetics and genomics competencies for public health
Inventory of family history tools and resources
. Behavioral and Psychosocial Programs (Financial
and Socioeconomic Factors)
(12–16)
. Advanced Risk Assessment (Renal, Inflammatory
Diseases)
(17,18)
. Subclinical Atherosclerosis Assessment (Imaging
and Nonimaging)
(17–20)
. Adherence and Disease Outcome Interdisciplinary
Programs
Patient compliance information for the professional
(21–24)
0. Nutrition Management (25–27)
1. Lipid Management (Management of Dyslipidemia) American Board of Clinical Lipidology
National Lipid Association Self-Assessment Program
(28)
2. Thrombosis Management See PAD Coalition and AHA for resources
(9,29–32)
3. Hypertension Management (33–35)
Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology
and Prevention
4. Smoking Cessation (2,36–38)
Links to MEDLINE and access to multiple governmental and professional Web sites for smoking cessation
support and literature
AHA Web site: Smoking and Cardiovascular Disease: includes educational resources for smoking
cessation
5. Obesity Management (Behavioral Programs) (39–41)
6. Exercise Physiology, Physical Activity
Management, and Cardiac Rehabilitation
(Secondary Prevention)
American College of Sports Medicine Annual Meetings and Regional Conferences
American Association of Cardiovascular and Pulmonary Rehabilitation Annual Meeting and resource
materials
AHA Annual Scientific Sessions
AHA Guidelines and Statements on Exercise
7. Prediabetes, Metabolic Syndrome, Insulin
Resistance, and Diabetes Management
American Diabetes Association (ADA) clinical practice guidelines
ADA Professional Practice Resources
(42)
Diabetes (Personal Health Decisions) PHD risk assessment tool
ADA for healthcare professionals
American Association of Clinical Endocrinologists
8. Chronic Disease Management (43)HA indicates American Heart Association.
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September 29, 2009:1336–63 Competence and Training for Prevention of CVDzability of that evidence. In this endeavor, the related field
f biostatistics provides important principles for appropriate
esign of clinical trials, interpretation of trial results, and the
ffective use of screening, diagnostic, and prognostic tools in
he practice of preventive cardiology (56).
.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Terms used to describe the central tendency of popula-
tion distributions (e.g., mean, median, and mode), and
the terms used to describe the magnitude of dispersion
around these measures (e.g., standard deviation, standard
error, and percentiles) (51–56). Familiarity with terms that
describe the frequency and burden of CVD as well as the
importance of age adjustment.
. Terms used to characterize screening and diagnostic tests
including sensitivity, specificity, accuracy, and predictive
values (positive and negative) (56,57).
. Experimental study designs (randomized, nonrandom-
ized, and noninferiority clinical trials) and nonexperi-
mental designs (cohort, case-control, nested case-control,
cross-sectional studies), as well as the principle of hypoth-
esis testing that underlies these studies, and the number
needed to treat and the number needed to harm.
. Common analyses encountered in the medical literature
such as the t test, chi-square test, multiple regression,
Kaplan-Meier survival analysis, and the Cox propor-
tional hazards analysis is necessary, including the types of
errors that can be committed when inferences are made
about data in studies.
. Traditional risk factors (8–10) and nontraditional risk
factors, such as calculation of non–high-density lipopro-
tein cholesterol (non–HDL-C) in persons with triglyc-
eride levels above 200 mg/dL.
. Inflammatory biomarkers, including high-sensitivity
C-reactive protein, serum amyloid A, interleukin-6,
lipoprotein-associated phospholipase A2, monocyte che-
moattractant protein-1, soluble CD40 ligand, and my-
eloperoxidase and their possible utility in risk assessment
(58,59).
. The concepts of relative and absolute risk; short-term,
long-term, and lifetime risk; and the population burden
of CVD attributable to specific risk factors, including the
Framingham Risk Assessment score in clinical practice
and knowledge of its limitations (60).
. Cost-benefit analyses of CVD interventions.
. Cardiovascular Pharmacology (Complex
ultipharmacologic Understanding)
.1. Justification
nowledge of cardiovascular pharmacology and the basic
rinciples of pharmacokinetics, pharmacodynamics, and
harmacogenomics is critical to the targeted application ofrug therapy for individual patients. A basic knowledge of
rug interactions, anticipated side effects, and dosing regi-
ens in a heterogeneous mix of complex patients is neces-
ary to integrate new research and new approaches for CVD
revention and treatment. The challenges posed by age,
ender, reproductive hormones, and medical comorbidities,
ncluding the coexistence of disorders known to contribute
o cardiac and vascular endothelial dysfunction, must be
ecognized. Interactions between medication and nutrition
e.g., grapefruit), over-the-counter supplements (e.g., anti-
xidant vitamins), nutriceuticals (e.g., stanol/sterol esters),
nd dietary alcohol intake are increasingly reported and of
ractical relevance. Knowledge that pharmacologic thera-
ies may have differing impact based on underlying exis-
ence of disease and endogenous hormone status, including
ormonal therapies, is important. A basic understanding of
harmacology will also be important as new therapies for
yocardial salvage, regeneration, and remodeling become
vailable.
.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Pharmacological approaches to lipids, hypertension,
thrombosis, diabetes and insulin resistance, cigarette
smoking cessation, and obesity (10). The important role
of statins and other lipid-lowering medications, anti-
platelet therapies, renin-angiotensin-aldosterone system
agents, and antihypertensive medications should be con-
sidered (49).
. Use of multiple drug combinations (coexistent condi-
tions and risk factor clustering) (61) and drug–drug
interactions (62), including the ever-increasing complex-
ity of pharmacological regimens and potential and real-
ization of drug–drug interactions.
. Preventive cardiovascular strategies for comorbidities
such as renal disease, autoimmune inflammatory disor-
ders, diabetes mellitus, and cancer, which raise the risk
for CVD due to the comorbidity itself as well as the
treatment regimens used to treat these comorbidities.
. Pharmacologic dosing adjustment in consideration of
issues of aging (63), gender (64), ethnicity, and comor-
bidities, for example, renal disease and liver disease and
ethnicity. Aggressive preventive cardiovascular regimens
are optimally tolerated when body weight– and renal
function–adjusted, including the elderly, women, and
smaller-sized men. Knowledge of ethnic groups that
have higher rates of toxicity to certain medications is also
important.
. Pharmacological interactions with over-the-counter sup-
plements, nutriceuticals (soluble fiber, psyllium seed,
stanol/sterol esters), and common dietary ingredients,
such as grapefruit, which can interact with many com-
mon medications, including most statins, increasing
blood levels of the medication when taken concurrently
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Competence and Training for Prevention of CVD September 29, 2009:1336–63(65). A majority of patients are taking over-the-counter
supplements that may interact with their medication,
such as the antioxidant vitamins that adversely interact to
reduce the antiatherosclerotic niacin benefit.
. Pharmacogenomics, including the prospective role of
patient testing for genetic polymorphisms that raise/
lower the likelihood of adverse pharmacological side
effects, or lack of metabolism/efficacy with a particular
class of medications.
. Genetics and Cardiovascular Disease in
ndividuals and Families
.1. Justification
enes and gene–environment interactions play important
oles in the causation, pathogenesis, and prognosis of CVD
6,66). Thus, knowledge of the spectrum of inherited
usceptibilities to CVD and elucidation of the patterns of
nheritance for specific genetic abnormalities may provide
mprovements in early detection, risk stratification, and
revention of CVD in individual patients and their family
embers (6,66–68). Additionally, advances in pharmaco-
enomics provide an opportunity for improving disease
reatment and response (69,70).
A wide spectrum of CVD with inherited genetic suscep-
ibilities is now known, and the advances made over the last
5 years in understanding the genetic basis of these disor-
ers provide a rationale for ensuring competence in genetics
or experts in the prevention of CVD (71–73). The limita-
ions of current genetic information in patient care and the
aps between knowledge of an apparently inherited suscep-
ibility and the availability of, or access to, corresponding
ffective treatments must be explicitly acknowledged (74).
inally, the benefits, risks, and costs associated with knowl-
dge of a patient’s genetic susceptibility to CVD and the
thical implications of referral for genetic testing and
ounseling must be recognized (75,76).
.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Basic skills in eliciting a comprehensive family history
during the patient encounter and familiarity with
clinical tools and/or questionnaires for collecting ge-
netic information.
. Differences between genotype and phenotype and the
concepts of dominance, recessiveness, X-linked inheri-
tance, genetic heterogeneity, and penetrance.
. Basic principles of clinical genetics including the types of
family studies, linkage analyses, genetic association stud-
ies, and familiarity with recent advances in genome-wide
association.
. Chromosomal deletions, duplications, and rearrange-
ments as a cause of clinical syndromes associated with
genetic disorders. o. Mendelian disorders and syndromes associated with con-
genital heart disease (e.g., DiGeorge, Noonan, and Wil-
liams syndromes) and those involving connective tissue
(e.g., Marfan syndrome, Ehlers-Danlos syndrome).
. Genetic basis of specific cardiovascular disorders such as
cardiomyopathies, arrhythmias, and lipoprotein disor-
ders and their potential role in diagnostic evaluation and
treatment.
. Teratogens including warfarin, hydantoin, retinoic acid,
valproic acid, rubella, and alcohol.
. The indications for, as well as benefits, risks, and ethical
implications of, referral for genetic testing and counsel-
ing, and the limitations of available testing kits.
. Behavioral and Psychosocial Programs
Financial and Socioeconomic Factors)
.1. Justification
sychosocial factors add a significant dimension to CVD
evelopment and outcomes (13,14,77–80). Psychosocial
actors influence the pathophysiology of disease, access to
ealthcare services, and adherence to treatment (81,82).
he best treatments are of no use to a patient if he or she
annot access the healthcare system, has inadequate services,
r obtains health care too late to change the outcome
15,16,83–85).
Prospective cohort studies provide evidence for a role for
epression, stress, psychosocial work characteristics, social
solation and support, and possibly hostility as factors in the
tiology of CVD and prognosis after CVD diagnosis
13,14,77–80). Over 30% of all patients with diagnosed
ardiovascular or cerebrovascular disease have either clinical
epression, anxiety, or other psychologically adverse condi-
ions (13,14). Depression is common overall, and risk is
ncreased following a CVD event (14,78,80). Depression is
risk factor for coronary heart disease (CHD), recurrent
HD events, and heart failure (HF), and is associated with
oor outcomes in CVD, postcoronary bypass, and HF.
ocioeconomic factors such as education, occupation, in-
ome, and insurance status have a significant impact on risk
actor development, CVD, and mortality (77,86–90).
All physicians and other healthcare providers should be
ble to diagnose anxiety and depression, and this should be
outine after a CVD event or stroke (14). While psycho-
ogical and medical interventions to treat depression and
nxiety have not been shown to reduce future cardiac events
o date, further research is underway to determine if
utcomes after CVD events benefit from treatment
14,16,83,84,91). Cardiac rehabilitation programs that in-
orporate psychosocial screening and intervention can im-
rove treatment outcomes, the quality of life, and adherence
f patients with psychological disorders (15,92).
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September 29, 2009:1336–63 Competence and Training for Prevention of CVD.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Psychosocial factors in the development of CVD and on
CVD outcomes, particularly as barriers to treatment
implementation.
. The diagnosis of anxiety and depression disorders, recog-
nition of suicidality, and the appropriate use of referrals.
. Use of pharmacotherapies in the treatment of depression
including patient selection, side effects, monitoring for
efficacy, and impact on risk factors.
. Recognition of safe treatments for anxiety and depres-
sion in patients with CVD.
. Recognition of when referral for psychiatric or psycho-
logic care is needed and appropriate.
. Cardiac rehabilitation for the assessment and manage-
ment of psychosocial conditions related to CVD.
. The role of healthcare systems and financing on psycho-
social risks and outcomes for CVD, including the role of
social workers and case managers in identifying and
facilitating social services.
. Advanced Risk Assessment
Renal, Inflammatory Diseases)
.1. Justification
he assessment of both traditional and nontraditional risk
actors underlies the primary and secondary prevention of
VD. Novel biomarkers are emerging as prognostic tools
or CVD risk assessment. Persons with chronic kidney
isease are considered to be a CHD risk equivalent by some
uidelines (93,94). The doses of many cardiovascular med-
cations need to be adjusted in persons with chronic kidney
isease, especially as glomerular filtration rate declines and
hronic kidney disease worsens.
Adults with inflammatory diseases such as lupus, psoria-
is, or rheumatoid arthritis seem to be prone to accelerated
therothrombotic vascular disease (95,96). Healthcare pro-
iders need to be more aggressive in trying to motivate patients
ith chronic kidney disease or inflammatory disorders to
ptimize their lifestyle habits and to achieve optimal levels of
lood pressure and lipids. A number of ongoing studies are
rying to assess the role of chronically high levels of inflamma-
ion in the development of CVD. Persons with lupus may also
eed to be screened for a prothrombotic state.
Recent studies have also shown that acute myocardial
nfarction (MI) rates and cardiovascular risk factors are
ncreased in persons with human immunodeficiency virus
HIV) infection as compared with non-HIV patients
97,98). Certain classes of antiretroviral drugs, especially
rotease inhibitors, appear to promote dyslipidemia and
ay independently increase risk via inflammatory pathways99). Strategies to reduce risk for atherosclerotic vascular eisease should be incorporated into the standard care of
IV infection.
There is considerable ongoing research dealing with the
rognostic role of biomarkers in persons with renal, inflam-
atory, or chronic infectious disease in both the primary
nd secondary prevention settings. In future years, we will
ave a better understanding of when measurement of
iomarkers such as C-reactive protein, B-natriuretic pep-
ide, and urinary microalbumin should change standard
linical management and the intensity of risk factor modi-
cation (100–102).
.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Measurement of urinary albumin creatinine ratio in
changing pharmacologic management.
. Inquiry regarding erectile difficulties on at least a yearly
basis as a marker for early atherosclerotic vascular disease
and generalized endothelial dysfunction.
. Measurement of systolic blood pressures in each brachial
artery and one of the pedal arteries in each foot to
calculate an ankle-brachial index, and the therapeutic
implications for diagnosis of peripheral vascular disease,
a CHD risk equivalent.
. Individuals with certain infectious diseases, chronic in-
flammatory conditions, and other collagen vascular dis-
eases, as they are often at increased risk for atheroscle-
rotic vascular disease and need to undergo comprehensive
risk factor modification (97).
. Aggressive management of all risk factors, as appropri-
ate, in patients with a history of chest wall irradiation, as
they are prone to premature atherosclerotic disease.
. Subclinical Atherosclerosis Assessment
Imaging and Nonimaging)
.1. Justification
he preclinical detection of atherosclerosis is an area of
rowing interest. The concept is to detect lesions in the
erebral, coronary, or peripheral vasculature before symp-
oms of end-organ ischemia occur (transient ischemic at-
ack/stroke, angina/MI, claudication/limb ischemia), or be-
ore rupture and bleeding (aortic aneurysm) (19,20,103).
wo recent studies from the MESA (Multi-Ethnic Study
f Atherosclerosis) trial have clearly documented the prog-
ostic power of elevated coronary calcium scores (104,105).
uch patients could be targeted for intensive risk factor
ontrol, other medical interventions, and endovascular or
urgical treatments if indicated.
While the concept of preclinical detection is appealing for
everal reasons, controversy exists about the usefulness and
fficacy of some screening programs and paradigms. The
reventive cardiovascular specialist should have the knowl-
dge base and skills to 1) advise patients about the useful-
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Competence and Training for Prevention of CVD September 29, 2009:1336–63ess of such screening, including costs; 2) interpret the
esults of a screening test in terms of formulating a care
lan; and 3) provide guidance about the need for subsequent
esting and therapy.
Some screening approaches entail financial as well as
otential medical risks, particularly if a positive test leads to
urther investigations and in some cases medical, surgical, or
ndovascular interventions. Thus, it is important to have
ome guidance about what competencies are needed in these
reas.
.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. General epidemiology and risk factors for asymptomatic
disease in various vascular beds. Knowledge of these factors
and associations will be helpful to the clinician in determin-
ing which patients are at higher versus lower risk to have
asymptomatic disease in various vascular beds.
. While controversial as to efficacy, the potential screening
modalities for asymptomatic disease in the various vas-
cular beds (Table 3) (18,20,106–118).
. Technical limitations and overall sensitivity, specificity,
accuracy, and risks of various screening tests (106,111,
113,118,119). Radiation exposure from coronary com-
puted tomography angiogram may increase the risk of
breast cancer, but the amount of ionizing radiation
associated with the test is considerably less than that
associated with a stress radionuclide examination (120).
Knowledge of these factors is important for the clinician
to weigh the results and risks of such screening tests and
determine the need for further testing depending on the
overall clinical scenario.
. The need for further testing in patients with evidence of
asymptomatic disease (Table 3). This would include the
clinical indications for further testing, the methods used
for subsequent testing, and their limitations (false posi-
tives, false negatives, overall accuracy) (103,108,118).
. How to treat patients with the presence of asymptomatic
disease in various vascular beds, the risks and benefits of
these various treatments and interventions, and patient
education and knowledge of sources for such educational
information (i.e., Web sites, nonprofit organizations).
. How to order and/or interpret the above screening tests,
understand the test results, explain their meaning to the
patient, and plan further testing and treatment, perhaps
able 3. Testing Modalities
Vascular Bed Initial Testing
arotid Auscultation, carotid duplex ultrasound
oronary CAS, CTA
orta Palpation, abdominal ultrasound
oncerebral peripheral arteries Ankle-brachial indexAS indicates coronary artery calcium score; CTA, computed tomography angiogram; MRA, magnetic rein consultation with other medical specialists in related
areas of vascular medicine.
. Adherence and Disease Outcome
nterdisciplinary Programs
.1. Justification
dherence is a measure of how consistently a patient
ollows the specific requirements of an intervention. Knowl-
dge about how to achieve a superior level of adherence is
rucial. While the true rate of patient adherence is difficult
o measure without using sophisticated tools that in them-
elves may influence patient behaviors, research generally
ndicates that long-term adherence to behavioral and med-
cal intervention may be as low as 50% (121). Nevertheless,
n some settings and in some patients much higher rates of
dherence occur, suggesting that low rates of adherence
esult from specific causal factors such as the cost of
edications, depression, or low health literacy, and that
dherence is amenable to change. Some personal factors
uch as personality traits do not consistently influence
dherence while others such as self-efficacy do. Societal,
ealthcare system, and provider factors likely influence
dherence rates (122–124). Successful prevention often
equires lifelong actions by the patient, and therefore, a high
evel of long-term adherence is very important in effective
revention (125).
Disease outcome or management programs usually con-
ist of at least 2 program elements: a patient monitoring
omponent and a system to respond proactively to changes
n the patient’s symptoms or physical status. Effective
isease management programs should reduce or delay the
dverse consequences of chronic CVD events, such as
reventing or reducing the number of HF hospitalizations
n patients with HF, and reduce the episodic nature of
ealth care based on the treatment of acute episodes (21).
he long-term efficacy of most disease programs is uncer-
ain. Since many patients have several chronic illnesses or
omplex prevention problems, the concepts underlying dis-
ase outcome interdisciplinary programs may in the future
e applied to a wider set of prevention problems. Both
dherence and disease outcome management programs are
ased on the integration of biologically derived scientific
oncepts with behavioral and social science concepts.
Follow-Up Tests
, CTA, carotid angiography, if indicated
ss test with or without imaging, if indicated; coronary angiography, if indicated
, MRA
dmill exercise test, PVRs, duplex ultrasound, CTA, MRAMRA
Stre
CTA
Treasonance angiography; and PVRs, pulse volume recordings.
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September 29, 2009:1336–63 Competence and Training for Prevention of CVD.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. How to measure adherence through a variety of ap-
proaches such as history and medication reconciliation.
. How to determine the causal factors underlying nonad-
herence, including the important patient factors such as
health literacy, depression, comorbid conditions, trust in
the healthcare provider, adverse effects, and economic
factors.
. Patient-level interventions to improve adherence such as
reducing the cost of medications, treating depression,
and use of aids like weekly pill boxes.
. Important provider factors such as interest in adherence
and skill in identifying barriers to adherence, combined
with understanding important healthcare system and
societal factors such as ease of maintaining the interven-
tion or medication, cost, systematic reminders, and
number and frequency of patient contacts.
. Components of a successful disease outcome program
such as prompt evaluation and detection of new symp-
toms and adjustment of medications in response to
changes in symptoms; frequency and duration of patient
interactions with the disease management program; and
mode of collecting information on patient status, includ-
ing self-reports and automated devices.
. Disease management programs, the role of feedback to
the patient and provider beyond adjustment of therapeu-
tic regimen, and the expected roles of the patient and
their family, the provider, and other health personnel in
a disease management program.
. Common theoretical models for adherence and disease
management such as: Stages of Change (22), Wagner’s
Chronic Care Model (23), and Self Efficacy (24).
. Motivational interviewing and other patient empower-
ment techniques.
0. Nutrition Management
0.1. Justification
any of the conditions and disease states that affect
therosclerotic risk can be prevented or at least modified by
ietary interventions. These conditions and diseases include
besity and excess body weight, hypertension, lipid abnor-
alities, and diabetes. Even when conditions such as
ypertension and hyperlipidemia are established and require
harmacologic therapy, dietary manipulations can reduce
he dosage of medication required to achieve therapeutic
oals. Similarly, some nutritional supplements (e.g., red rice
east [126] and omega-3 fatty acids [127]) contain phar-
acologically active substances that can be used therapeu-
ically in selected patients. In contrast, some dietary and
utritional supplements may contain substances such as
ympathomimetics that increase cardiac arrhythmias. Con- tequently, healthcare providers practicing preventive cardi-
logy must be required to have an understanding of nutri-
ion and the principles of nutrition so that they are able to
rovide expert advice to patients and to reinforce expert
dvice given by nutritional professionals. In addition, cred-
bility as a preventive specialist with patients is enhanced
hen the preventive cardiologist is conversant in the basics
f diets and nutritional therapy.
0.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Obesity, its role in producing insulin resistance and the
metabolic syndrome, the healthcare provider’s role in
helping patients maintain body weight, the basic classi-
fications of body weight, the contribution of overweight
to hypertension and hyperlipidemia, the basic concepts
of caloric balance, the caloric content of the major food
groups, the role of exercise in helping to maintain body
weight, and the action of the available prescription
weight loss drugs and their possible cardiovascular side
effects, including that recommendations may differ ac-
cording to age (pediatric versus adult versus very elderly).
. Surgical approaches to morbid obesity and the possible
medical complications of this surgery.
. Composition of diets used to assist in blood pressure
control such as reduced sodium, calorie reduction for
weight loss, moderation of alcohol consumption, in-
creased potassium intake, and consumption of an overall
healthy diet (128).
. Composition of therapeutic diets used to manage hyper-
cholesterolemia and hypertriglyceridemia and especially
the effect of saturated fats, transfatty acids, and low
dietary fat and cholesterol on serum lipids (129). In
addition, the preventive cardiology specialist should be
conversant in discussing the origin of dietary fats with
regard to therapeutic potential (27,129).
. Composition of diets used in patients with impaired
glucose tolerance and diabetes (130).
. Use of over-the-counter and nonprescription agents in
lipid management including the risks and benefits of
plant stanols and sterols (131), fish oils (127), and dietary
fiber (127,132).
. Potential cardiac dangers of too-rapid weight loss (133).
. The limited role of dietary antioxidants in preventing
atherosclerotic disease (126,134).
. The role of alcohol intake in causing and preventing
cardiac disease (135,136).
1. Lipid Management
Management of Dyslipidemia)
1.1. Justification
he management of dyslipidemia has emerged as a key
herapeutic strategy to reduce both primary and secondary
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Competence and Training for Prevention of CVD September 29, 2009:1336–63ardiovascular events. Despite a plethora of large outcome trials
137–139) supporting the evidence for lipid-altering treat-
ents to improve outcomes and national guidelines that have
stablished specific goals of treatment, there remains a signif-
cant treatment gap in the achievement of low-density lipopro-
ein cholesterol (LDL-C), non–HDL-C, and HDL-C targets
140,141). The National Cholesterol Education Program
dult Treatment Panel III (NCEP ATP III) Guidelines (142)
pdated in 2004 (143) mandate an LDL-C goal for high-risk
atients of less than 100 mg/dL with an optional goal of less
han 70 mg/dL for patients with CVD plus diabetes or other
ultiple risk factors. The AHA Secondary Prevention Guide-
ines also advocate an LDL-C goal and non–HDL-C goal of
ess than 70 mg/dL and less than 100 mg/dL, respectively (10).
et, recent surveys demonstrate that less than one third of
atients with CVD with additional risk factors are achieving
hese recommended targets (140). In addition, patients with
ow HDL-C and/or elevated triglycerides remain at elevated
esidual risk even at recommended LDL-C goals (144–146).
1.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Basic lipid metabolism, including both exogenous and
endogenous lipoprotein synthesis.
. Synthetic process in which chylomicrons, very low-
density lipoprotein, LDL-C, and HDL-C are devel-
oped, and the genetic disorders that are associated with
dyslipidemia.
. The diagnosis of familial hypercholesterolemia, familial
combined hyperlipidemia, and familial hypoalphali-
poproteinemia, which are associated with a significantly
increased risk of premature atherosclerosis.
. Familiarity with NCEP guidelines, including the recent
updates that recommend optional LDL-C targets for
very high-risk patients.
. Matching the intensity of treatment to the risk of the
patient. This is the cornerstone of national guidelines,
and the preventive cardiovascular specialist should be
familiar with the clinical trials that provided the evidence
for more aggressive LDL-C reduction.
. Ability to instruct a patient on appropriate therapeutic
lifestyle changes, which includes an understanding of a
low saturated fat and dietary cholesterol food manage-
ment program and, if necessary, the incorporation of
viscous soluble fiber and plant stanols/sterols to further
lower LDL-C levels, and the importance of reducing
trans fats, cholesterol, and simple carbohydrates in pa-
tients with high triglycerides and abdominal obesity.
. Mechanism of action of statins, the expected efficacy of
each dose of statin and, therefore, the ability to achieve
the NCEP ATP III goals, plus the mechanism of action
of niacin, ezetimibe, fibrates, bile acid sequestrants, and
omega-3 fatty acids and their expected effects onLDL-C, HDL-C, and triglycerides and risks and ben-
efits of combination therapy.
. Potential side effects of treatment to counsel patients and
avoidance of drug interactions, which is imperative to
improve the safety and compliance of long-term
treatment.
2. Thrombosis Management
2.1. Justification
therothrombosis is a progressive process that includes
therosclerotic plaque formation, disruption, and thrombo-
is. These processes constitute the pathophysiology that
nderlies acute coronary syndrome, ischemic stroke or
ransient ischemic attack, and peripheral arterial disease
PAD). U.S. prevalence data lists 7.2 million people affected
y MI, 6.5 million with angina pectoris, 5.5 million with
troke (147), and 8 to 12 million people affected by PAD
148). The NCEP ATP III considered PAD to be a CHD
isk equivalent (142). The recently published REACH
Reduction of Atherothrombosis for Continued Health)
egistry showed that among patients with symptomatic
therothrombosis, 16% had symptomatic polyvascular dis-
ase (149). Approximately 56% of stroke patients 60 years of
ge and older have coexisting coronary artery disease
CAD), and evidence suggests the 20% to 40% of patients
ith ischemic stroke or transient ischemic attack concur-
ently have silent CAD (150,151).
2.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. The core set of risk factors, which includes hypertension,
diabetes, hypercholesterolemia, tobacco use, and obesity,
that contribute to the bulk of the risk for atherothrom-
bosis (149), and novel parameters such as lipoprotein(a),
apolipoprotein A-I and apolipoprotein B-100, fibrino-
gen, homocysteine, and high-sensitivity C-reactive pro-
tein (10,152).
. Management of unstable angina and non–ST-segment
elevation MI is extensive with multiple antithrombotic
therapy combinations, and implement systems for anti-
thrombotic therapy recommended in the ACC/AHA
guidelines for unstable angina and non–ST-segment
elevation MI (153).
. Antithrombotic therapy options for preventing recurrent
stroke and other cardiovascular events in patients with
noncardioembolic ischemic stroke (32).
. Risk factor identification and early assessment of PAD
(149,152,154), and use of antithrombotic agents to
prevent atherothrombotic events in this patient population
(155–158), including their indications and contraindica-
tions, mechanism of action, efficacy, side effects, drug
interactions, and costs (159).
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3.1. Justification
ypertension is a major contributor to the global disease
urden and is one of the leading preventable causes of
remature death worldwide (160). In the United States, a
isproportionate burden of hypertension and its associated
omplications, including CHD, HF, stroke, and end-stage
enal disease and CVD mortality, affect African Americans
also referred to as U.S. blacks) (161). Preventive cardiovas-
ular specialists should have knowledge of hypertension and
echanisms of elevated blood pressure, and an understand-
ng of the therapeutic lifestyle changes and pharmacologic
nterventions that are crucial for controlling hypertension in
linical practice. A basic knowledge of the potential mech-
nisms of elevated blood pressure and associated risk factors
s necessary to understand the ongoing research into new
pproaches for prevention, identification, and therapy. A
asic understanding of the use of therapeutic lifestyle
hanges and appropriate drug therapies for patients with
ompelling indications is necessary to reduce cardiovascular
orbidity and mortality.
3.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Major risk factors for hypertension as described by the
Seventh Report of the Joint National Committee (35),
and the impact of hypertension on CVD morbidity and
mortality specifically related to MI, HF, stroke, and renal
failure, and the diagnostic categories and treatment goals.
. Therapeutic lifestyle and pharmacologic interventions in
hypertension and CVD including weight reduction,
adopting Dietary Approaches to Stop Hypertension
(DASH) eating plan, sodium reduction, physical activity,
moderation of alcohol consumption, and medication
regimens.
. Indications for and interpretation of ambulatory blood
pressure and home blood pressure monitoring.
. Definition and approach to white coat hypertension and
masked hypertension.
. Evaluation and treatment of identifiable causes of hyper-
tension (secondary hypertension), including chronic kid-
ney disease, coarctation of the aorta, glucocorticoid
excess states, pheochromocytoma, primary aldosteron-
ism, renovascular hypertension, sleep apnea, thyroid/
parathyroid disease, and drug induced or drug related.
. Definition, differential diagnosis, and treatment of resis-
tant hypertension.
. The findings of clinical trials in hypertension with
evidence supporting compelling indications and contra-
indications for antihypertensive drug classes.4. Smoking Cessation
4.1. Justification
moking remains the most important risk factor for CVD
n the world (162,163). It is estimated that 40% of all heart
isease is related to smoking (164,165). The biochemical
nd physiological consequences of smoking on CVD are
ell defined (164,166,167). Compelling evidence exists
emonstrating that smoking cessation is associated with
ignificant reversal of risk for CAD, stroke, and cancer-
elated deaths (162). In addition, there are multiple societal
onsequences from cigarette smoking, including enormous
conomic costs. In the United States alone, it is estimated
hat smoking costs $167 billion each year (162). Since 1965,
moking in the United States has declined by 47% among
eople over the age of 18 years. However, it is estimated
hat more than 23% of adult men and 19% of adult women
ontinue to smoke, and this number is rising in the young
162). In addition, exposure to secondhand smoke places
ignificantly more persons at risk for heart disease and
troke (168,169).
Clinical competency in smoking cessation treatment is
ritical for those whose expertise encompasses primary and
econdary prevention of CVD and stroke. Clinical competency
ncludes skills in patient education, counseling, and behavioral
hange, and knowledge of important pharmacotherapies, in-
luding risks and benefits. Clinical competency relies on the
dentification of smoking status in all patients, prompt and
efinitive advice to quit, and the implementation of smoking
essation counseling and pharmacotherapies. Systematic
ollow-up of all smokers at subsequent visits and the involve-
ent of healthcare professionals with smoking cessation ex-
ertise improves lifetime smoking cessation.
4.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Short- and long-term pathophysiological consequences
related to tobacco use, which include pulmonary and
cardiovascular diseases (36,166,167,170–176).
. Pathophysiology of smoking addiction and be knowl-
edgeable of the methods of assessing the physiologic
levels of nicotine addiction (e.g., Fagerstrom Question-
naire) (176).
. Use of behavioral skills that facilitate smoking cessation,
including interpersonal communication skills, behavioral
change techniques such as self-monitoring and self-care,
stress management counseling, patient contracting and
goal setting, self-efficacy, motivational interviewing, and
relapse prevention (170,174,176–178).
. Use of the 5 As (Ask, Advise, Assess, Assist, and
Arrange) treatment intervention during office visits.
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tion, and counseling (170,174,176).
. Use of pharmacologic therapies to support smoking
cessation based on age, pregnancy status, medical history,
and comorbidities of the patient (167,170,171,175,
179–183).
5. Obesity Management
Behavioral Programs)
5.1. Justification
besity is a disease that is reaching epidemic proportions,
ot only in the United States, but also elsewhere throughout
he world. At the present time, more than 60% of the U.S.
dult population is classified as either overweight or obese
39,184). In addition, childhood obesity is growing in an
larming fashion. Overweight and obesity are particularly
revalent in certain minority groups and in individuals of
ower socioeconomic status. Overweight is defined as a body
ass index of 25 to 29.9 kg/m2, and obesity as a body mass
ndex greater than 30 kg/m2 (40). Higher body weight is
ssociated with an increased risk of hypertension, hyperlip-
demia, stroke, CAD, insulin resistance, and type 2 diabetes
ellitus. Moderate weight loss has been shown to decrease
he severity of these comorbidities, and data from observa-
ional studies suggest a concomitant decrease in mortality
41,185).
Overweight and obesity are felt to result from an imbal-
nce between energy intake and expenditure. Less than 20%
f American adults regularly engage in moderate physical
ctivity. The AHA identified an “epidemiological triad” in
revention Conference VII (November 2004), which in-
ludes host factors (genetic makeup, age/gender, attitudes,
nd behavior), vectors for increased energy consumption or
ecreased energy expenditure (i.e., automobile travel instead of
alking or biking, large portion sizes, and high-fat and
igh-calorie foods), and environmental factors (i.e., cost of
oods, government policy, as well as sociocultural forces).
hey suggest that all components need to be addressed in
rder for successful prevention to occur (186).
A variety of behavioral options exist to manage over-
eight and obesity effectively. These include dietary ther-
py, physical activity, and behavioral techniques. To be
uccessful in achieving long-term weight maintenance,
owever, these methods have to be individually applied to
ach patient in the context of regular and consistent medical
upervision. Reduction of initial body weight by only 5% to
0% has been shown to result in significant cardiovascular
isk factor reduction (187), as well as a variety of other
ealth benefits. Presently, training on overweight/obesity in
pecialty and subspecialty medical education is woefully
nadequate.5.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
1. Assessment of the overweight/obese patient involves
calculation of body fatness, which can be estimated by
body mass index, waist circumference, overall cardio-
vascular risk status, as well as the patient’s motivation to
lose weight, including the methods for measurement of
these. Importance of documenting previous history of
weight loss attempts, social supports available, the
patient’s attitude toward and ability to perform physical
activity, as well as financial considerations that may
impact his or her attempts at weight loss.
2. Initial goal of weight loss therapy is to reduce body
weight by 7% to 10% over a 6-month period of time,
after which the rate typically declines. Knowledge that
reassessment should occur to determine if further
weight loss is desirable and that efforts at maintaining
weight loss must be put into place.
3. Caloric content and caloric balance of the major food
groups, the physiologic and pathologic effects of excess
body weight, and the principles of weight loss via reduced
caloric intake and increased caloric expenditure.
4. Combination of individually planned dietary, exercise,
and behavioral techniques, and when to use a low-
calorie diet versus a very-low-calorie dietary strategy
(188), as well as an understanding of exercise physiol-
ogy and guidelines for activity prescription, including
aerobic exercise and strength training (189).
5. Behavioral therapy, with the use of other healthcare
professionals, to include management/problem-solving
techniques for stress, enhancing social support, cogni-
tive restructuring, and promoting the ability to self-
monitor, as well as setting realistic goals.
6. Recognition that maintenance of weight loss is often
more difficult than the initial loss; thus, the practitioner
must be skilled at understanding the utility of a mul-
tifaceted program that consists of ongoing dietary
management, physical activity, as well as behavioral
management.
7. Challenges of treating special populations, such as
children/adolescents, the elderly, and smokers.
8. Guidelines for pursing pharmacologic or surgical means
of weight loss therapy if behavioral programs are not
successful.
9. Pharmacology, use, and side effects of weight loss
medications, both prescription and nonprescription.
0. Counseling of patients regarding the nutritional and
medical risks associated with rapid weight loss (par-
ticularly that mediated by surgical intervention) that
may impact CVD, including iron and B12 deficiency
anemia, folate deficiency, as well as the potential for
other deficiencies, including vitamin D and other
fat-soluble vitamins. Knowledge that physical fitness
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weight loss.
6. Exercise Physiology, Physical Activity
anagement, and Cardiac Rehabilitation
Secondary Prevention)
6.1. Justification
mportant goals of exercise-based cardiac rehabilitation are
o stabilize existing atherosclerotic plaques, improve endo-
helial function and lessen arterial inflammation by modu-
ating lipid/lipoprotein levels and blood pressure, and
chieve smoking cessation, if appropriate (190,191). Addi-
ional objectives are to: increase functional capacity, de-
rease symptoms, reduce body weight and fat stores, pro-
ote psychosocial well-being, and improve the ability of the
atient to return to work (192,193). Recent meta-analyses
ndicate that exercise-based cardiac rehabilitation improves
he cardiovascular risk factor profile and reduces all-cause
nd cardiovascular mortality, and that these benefits persist
n the current era of cardiovascular therapeutics (194).
In the past, only post-MI patients were considered
andidates for exercise-based cardiac rehabilitation. How-
ver, the proven benefits and safety of this intervention have
xpanded to include patients with angina, diabetes or
etabolic syndrome, cardiomyopathy, pacemakers, heart
alve replacement, concomitant pulmonary disease, cardiac
ransplant, and HF, as well as patients who have undergone
ercutaneous coronary intervention or coronary artery by-
ass graft surgery (191,192,195), yet these diagnoses are not
ll covered by health insurance.
Moderate-to-vigorous physical activity and improved car-
iorespiratory fitness reduce cardiovascular-associated mor-
idity and mortality by multiple mechanisms (189,195),
ncluding antiatherosclerotic, anti-ischemic, antiarrhythmic,
nd antithrombotic effects. Each 1 metabolic equivalent
MET) (1 MET  3.5 mL O2/kg/min) increase in exercise
apacity appears to confer an 8% to 17% reduction in
ortality (196). Alternatively, an approximate 1,000-kcal/
eek increase in activity confers the equivalent survival
enefit that would accrue by increasing cardiorespiratory
tness by 1 MET (197). Exercise testing may be helpful in
uantifying aerobic capacity and in establishing a safe and
ffective exercise prescription (198,199).
6.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
1. Prescription of exercise in primary prevention populations.
2. Evaluation, appropriate interventions, and expected
outcomes for each of the core components of contem-
porary cardiac rehabilitation/secondary prevention pro-
grams, including exercise training, risk factor modifica-
tion, medical surveillance/emergency support, and
psychosocial (e.g., stress management)/vocationalcounseling (200), as well as alternative delivery sources
(e.g., site-supervised versus home-based [telephone,
Internet, completion of exercise logs] programs) (191).
3. ACC/AHA current guidelines for secondary preven-
tion for patients with coronary and other atherosclerotic
vascular disease, including smoking cessation, blood
pressure control, lipid management, physical activity,
weight management, diabetes management, antiplatelet
agents/anticoagulants, renin-angiotensin-aldosterone
system blockers, beta blockers, and influenza vaccina-
tion (10).
4. Multidisciplinary team approach to implementing an
effective cardiac rehabilitation/secondary prevention
program (200,201).
5. Traits, emotional states, and life situations that have
been linked to CVD; for example, depression, anxiety,
anger/hostility, social isolation, vital exhaustion, and
chronic life stresses.
6. Stages of behavior change and the concept of motiva-
tional interviewing to enable patients to favorably mod-
ify long-standing, deleterious lifestyle habits.
7. Administration and interpretation of exercise tests as
per the ACC/AHA 2000 Clinical Competence State-
ment on Stress Testing (199), with specific reference to
the following variables: indications and contraindica-
tions; test end points; peak or maximal oxygen uptake;
hemodynamics; rating of perceived exertion; recogni-
tion of supraventricular and ventricular arrhythmias;
and interpretation of ST-segment displacement
(5,196,198,199). Competence includes the knowledge
and skills required for certification in AHA Basic and
Advanced Life Support.
8. Use of exercise test results for activity counseling and
exercise prescription (5,196,198).
9. Inverse relationship between physical activity and/or
cardiorespiratory fitness, expressed as mL O2/kg/min or
METs, and cardiovascular and all-cause mortality in
persons with and without known CAD (189,196,197).
0. Safety, benefits, rationale for and contraindications to
endurance training and resistance exercise in primary
and secondary prevention programs (5,196,198,202).
1. Basic terminology and fundamentals of exercise physi-
ology, with specific reference to the interpretation of
clinical exercise testing and the prescription of exercise
in health and disease (5,196,198).
2. Spectrum of cardiovascular conditions among patients
who require physical activity counseling and/or might
benefit from exercise training, including pathophysiol-
ogy, signs and symptoms of stable and unstable disease,
and medical and surgical treatments for the following
conditions: CAD, including recent MI, postpercutane-
ous coronary intervention and postcoronary artery by-
pass grafting; cardiomyopathy and HF; valvular heart
disease; peripheral arterial disease; hypertension; car-
diac arrhythmia; and cardiac transplantation.
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tent sitting/standing) in preventing deconditioning during
the hospital confinement period and early convalescence
after an acute coronary event or intervention (203).
4. Prescription of exercise (5,196,198), with respect to the
intensity (e.g., threshold or minimal effective dosage)
(204), frequency, duration, and modes of endurance
exercise training, as well as lifestyle physical activity
(205) and appropriate tracking modalities (e.g., pedom-
eters) with specific reference to those patients with
cardiovascular conditions as listed above.
5. Comorbidities and how they might affect exercise
prescription and performance. This is especially impor-
tant in diabetes mellitus, chronic pulmonary disease,
and dialysis-dependent chronic kidney disease.
6. Application of the elements of risk stratification (e.g.,
ejection fraction, signs/symptoms of myocardial isch-
emia, cardiorespiratory fitness) in triaging coronary
patients to varied degrees of monitored/supervised
exercise-based rehabilitation programs (191–193).
7. Variables that influence a patient’s participation in and
adherence to an exercise-based cardiac rehabilitation
program (191), including the importance of physician
support and encouragement (201).
8. Selected high-intensity, anaerobic-type domestic, occu-
pational, or recreational activities (e.g., running, racquet
sports, snow removal) may pose an increased risk of
acute cardiovascular events, especially in habitually
sedentary persons with known or occult CAD (206).
9. The role that physical activity plays as primary preven-
tion for CVD as a public health measure.
7. Prediabetes, Metabolic
yndrome, Insulin Resistance,
nd Diabetes Management
7.1. Justification
here are very strong epidemiological data available to
upport the concept that type 2 diabetes is associated with
reatly increased risk of cardiovascular events. In addition,
atients with type 1 diabetes of long duration, with other
omplications, are also at risk for cardiovascular events.
everal clinical trials have assessed the effect of glycemic
ontrol on long-term microvascular complications, includ-
ng CVD. Good glycemic control utilizing effective insulin
egimens in type 1 diabetes may prevent CVD, and trials of
he effect of intensive therapy on CVD in type 2 diabetes are
n progress. The metabolic syndrome, prediabetes, and
nsulin resistance also portend an elevated risk of CVD.
7.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in: a. The understanding of molecular and cellular mecha-
nisms of impaired glucose tolerance, hyperinsulinemia,
metabolic syndrome, and overt diabetes.
. Methods of cardiovascular risk assessment in diabetic
patients, including risk engines and other tools devel-
oped to assess cardiovascular risk in patients with type 2
diabetes.
. Adherence and disease outcome interdisciplinary pro-
grams that meet the educational standards recommended
by the ADA. Such programs may be effectively inte-
grated with weight management programs and other risk
factor management education strategies.
. Principles of diabetes management, both behavioral and
pharmacological, and multiple resources that are avail-
able from organizations such as the ADA and American
Association of Clinical Endocrinologists that are avail-
able on Web sites for both patients and healthcare
professionals.
. Criteria for effective screening and diagnosis of predia-
betes, insulin resistance, and metabolic syndrome (207),
including the several definitions for the metabolic syn-
drome that have been recommended.
. Identification of patients at risk for type 2 diabetes,
understanding treatment and when to refer to a special-
ist. Management of prediabetes consists of lifestyle changes
(208).
. Management of overt diabetes, including the goals for
metabolic control standards of care for people with
diabetes, essential clinical and laboratory tests and re-
quirements for screening for complications, and individ-
ualized pharmacological therapy that are regularly pub-
lished and updated by the ADA and other organizations
(209).
. Implementation of guidelines regarding maintenance of
normoglycemia in the intensive care unit setting (210).
8. Chronic Disease Management
8.1. Justification
atient-specific and systems approaches to the primary and
econdary prevention of CVD are essential for optimal
therosclerosis disease management (211–213). This type of
pproach must encompass a simple and meaningful strategy
or both patient and provider throughout the process of risk
ssessment and intervention (medication management and
ifestyle modification) (214). Guidelines are based on the
esults of randomized trials (10).
Too often, providers forget to implement the standard
uidelines that deal with antiplatelet therapy, antihypertensive
herapy, lipid-lowering therapy, and lifestyle changes; all of
hese items are important in improving the quality of medical
are. As a profession, we need to improve the frequency with
hich evidence-based guidelines are applied in clinical prac-
ice. Many guidelines have been published, but there has been
disappointing lack of standard implementation.
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September 29, 2009:1336–63 Competence and Training for Prevention of CVDBasic physician education and passive dissemination of
uidelines alone are generally insufficient to sustain quality
mprovement. Chart audit and feedback of results, reminder
ystems to consider use of specific medicines or tests, and the
se of local opinion leaders have had variable results. Multi-
actorial interventions that simultaneously attack different bar-
iers to change tend to be more successful than isolated efforts.
issemination of practice guidelines and knowledge of cardio-
ascular prevention must be accompanied by more intensive
ducational and behavioral interventions to maximize the
hances of improving physician practice patterns.
The AHA has endorsed the Get With The Guidelines
pproach, and the ACCF has endorsed an approach to the
anagement of chronic stable angina and the prevention of
VD in general (212,215). These approaches should help
edical practices and the individual patient better under-
tand the various pharmacologic therapies available for a
iven individual condition.
The ACCF Guidelines Applied in Practice (GAP) pro-
ram is also a well-conceived systems approach that has
een focused on patients presenting with acute coronary
yndromes (216–218). The same principles of prompt
nitiation of antiplatelet therapy, beta blockade, inhibition
f the renin-angiotensin-aldosterone system, cholesterol-
owering therapy, and better dietary and exercise habits can
lso be modified for use in chronic management of persons
ith atherosclerotic vascular disease (219–221).
8.2. Minimal Knowledge
he expert in the prevention of CVD should demonstrate
nowledge and competence in:
. Existing patient-specific, systems approaches to preven-
tion of CVD, including:
• The implementation of the AHA’s Get With The
Guidelines.
• Chronic disease management programs specific to
CVD.
• The basics of the chronic care model applied to CVD
prevention (222–224).
• Understanding of current performance measures for
primary and secondary prevention of CVD in all
practice settings.
• Implementation of performance improvement
measures.
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